Pharmacodynamic comparison of pantoprazole enantiomers: Inhibition of acid-related lesions and acid secretion in rats and guinea-pigs

Journal of Pharmacy and Pharmacology

Volumn 57, Issue 7, 2005, Pages 923-927

  Cao, Hong ^a   Wang, Min Wei ^a   Sun, Li Xin ^a   Ikejima, Takashi ^a   Hu, Zhi Qing ^b   Zhao, Wei Hua ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE; PANTOPRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG STRUCTURE; ENANTIOMER; GUINEA PIG; INTESTINE ULCER; MALE; NONHUMAN; PHARMACODYNAMICS; PYLORUS LIGATION; RAT; REFLUX ESOPHAGITIS; STOMACH ACID SECRETION; STRUCTURE ACTIVITY RELATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; ESOPHAGITIS, PEPTIC; GASTRIC ACID; GASTRIC FISTULA; GUINEA PIGS; ISOMERISM; MALE; OMEPRAZOLE; PROTON PUMPS; RATS; RATS, SPRAGUE-DAWLEY; STOMACH ULCER; SULFOXIDES;

EID: 21044431896     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357056361     Document Type: Article

References (29)

1. Andersson, T., Hassan-Alin, M., Hasselgren, G., Rohss, K., Weidolf, L. (2001a) Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. 40: 411-426
2. Andersson, T., Rohss, K., Bredberg, E., Hassan-Alin, M. (2001b) Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment. Pharmacol. Ther. 15: 1563-1569
3. Beil, W., Staar, U., Sewing, K. F. (1992) Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability. Eur. J. Pharmacol. 218: 265-271
4. Bochenek, W. J., Peters, S., Fraga, P. D., Wang, W., Mack, M. E., Osato, M. S., El-Zimaity, H. M., Davis, K. D., Graham, D. Y.; Helicobacter pylori Pantoprazole Eradication (HELPPE) Study Group (2003) Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter 8: 626-642
5. Brunner, G., Harke, U. (1994) Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment. Pharmacol. Ther. 8 (Suppl. 1): 59-64
6. Cao, H., Wang, M., Jia, J., Wang, Q., Cheng, M. (2004) Comparison of the effects of pantoprazole enantiomers on gastric mucosal lesions and gastric epithelial cells in rats. J. Health Sci. 50:1-8
7. Cheer, S. M., Prakash, A., Faulds, D., Lamb, H. M. (2003) Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 63: 101-133
8. Cunningham, K. M., Horowitz, M., Riddell, P. S., Maddern, G. J., Myers, J. C., Holloway, R. H., Wishart, J. M., Jamieson, G. G. (1991) Relations among autonomic nerve dysfunction, oesophageal motility, and gastric emptying in gastrooesophageal reflux disease. Gut 32: 1436-1440
9. Drayer, D. E. (1986) Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clin. Pharmacol. Ther. 40: 125-133
10. Eagleton, G. B., Watt, J. (1965) Acute gastric ulceration in the guinea-pig induced by a single intraperitoneal injection of aqueous histamine. J. Pathol. Bacterial. 90: 679-682
11. Fitton, A., Wiseman, L. (1996) Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 51: 460-482
12. 2-antagonists and omeprazole. Jpn. J. Pharmacol. 49 (Suppl.) 193P
13. Hassan-Alin, M., Andersson, T., Bredberg, E., Rohss, K. (2000) Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur. J. Clin. Pharmacol. 56: 665-670
14. Huber, R., Kohl, B., Sachs, G., Senn-Bilfinger, J., Simon, W. A., Sturm, E. (1995) Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment. Pharmacol. Ther. 9: 363-378
15. Katsuki, H., Yagi, H., Arimori, K., Nakamura, C., Nakano, M., Katafuchi, S., Fujioka, Y., Fujiyama, S. (1996) Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm. Res. 13: 611-615
16. Kromer, W., Postius, S., Riedel, R., Simon, W. A., Hanauer, G., Brand, U., Gonne, S., Parsons, M. E. (1990) BY 1023/ SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J. Pharmacol. Exp. Ther. 254: 129-135
17. Lind, T., Rydberg, L., Kyleback, A., Jonsson, A., Andersson, T., Hasseigren, G., Holmberg, J., Rohss, K. (2000) Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 14: 861-867
18. Malfertheiner, P., Kirchner, T., Kist, M., Leodolter, A., Peitz, U., Strobel, S., Bohuschke, M., Gatz, G.; BYK Advanced Gastric Ulcer Study Group (2003) Helicobacter pylori eradication and gastric ulcer healing - comparison of three pantoprazole-based triple therapies. Aliment. Pharmacol. Ther. 17: 1125-1135
19. Masubuchi, N., Yamazaki, H., Tanaka, M. (1998) Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats. Chirality 10: 747-753
20. Nerurkar, S. G., Dighe, S. V., Williams, R. L. (1992) Bioequivalence of racemic drugs. J. Clin. Pharmacol. 32: 935-943
21. Ogilvie, A. L., James, P. D., Atkinson, M. (1985) Impairment of vagal function in reflux oesophagitis. Q. J. Med. 54: 61-74
22. Pilotto, A., Leandro, G., Franceschi, M.; Ageing and Acid-Related Disease Study Group (2003) Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole. Aliment. Pharmacol. Ther. 17: 1399-1406
23. Richardson, P., Hawkey, C. J., Stack, W. A. (1998) Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 56: 307-335
24. Simon, W. A., Budingen, C., Fahr, S., Kinder, B., Koske, M. (1991) The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole. Biochem. Pharmacol. 42: 347-355
25. Shay, H., Komarov, S. A., Fels, S. S., Meranze, D., Gruenstein, M., Siplet, H. (1945) A simple method for the uniform production of gastric ulceration in the rat. Gastroenterology 5: 43-61
26. Steinijans, V. W., Huber, R., Hartmann, M., Zech, K., Bliesath, H., Wurst, W., Radtke, H. W. (1994) Lack of pantoprazole drug interactions in man. Int. J. Clin. Pharmacol. Ther. 32: 385-399
27. Tanaka, M., Yamazaki, H. (1996) Direct determination of pantoprazole enantiomers in human serum by reversed-phase high-performance liquid chromatography using a cellulose-based chiral stationary phase and column-switching system as a sample cleanup procedure. Anal. Chem. 68: 1513-1516
28. Tanaka, M., Yamazaki, H., Hakusui, H., Nakamichi, N., Sekino, H. (1997) Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole - a preliminary study. Chirality 9: 17-21
29. Tanaka, M., Ohkubo, T., Otani, K., Suzuki, A., Kaneko, S., Sugawara, K., Ryokawa, Y., Ishizaki, T. (2001) Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clin. Pharmacol. Ther. 69: 108-113